Comparable stake leader
AVENIR CORP
SEC ownership of Cytosorbents Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001175151.
Disclosed value leader
Thomas A. Satterfield Jr.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CTSO on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
AVENIR CORP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
AVENIR CORP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001175151
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cytosorbents Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AVENIR CORP
Disclosed value leader
Thomas A. Satterfield Jr.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 8.3%
13D/G row: AVENIR CORP
Showing 1-8 of 50 holder rows.
Quick read
AVENIR CORP leads the comparable SEC ownership view at 8.3%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AVENIR CORP's linked filing trail.
Comparable ownership
Top 5
AVENIR CORP
8.3%
Thomas A. Satterfield Jr.
6.6%
Avenue Venture Opportunities Fund...
5.7%
Skylands Capital, LLC
4.8%
VANGUARD GROUP INC
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AVENIR CORP |
13D/G
13F
Company
|
8.3%
|
$3,817,972
5,230,099 shares
|
+$1,559,392 | 31 Dec 2025 |
| Thomas A. Satterfield Jr. |
13D/G
|
6.6%
|
$4,638,686
3,998,867 shares
|
$0 | 13 Jan 2025 |
| Avenue Venture Opportunities Fund, L.P. |
13D/G
Avenue Capital Management II, L.P.
|
5.7%
|
$4,356,117
3,755,273 shares
|
$0 | 26 Jun 2024 |
| Skylands Capital, LLC |
13D/G
13F
Company
|
4.8%
|
$3,483,134
3,002,702 shares
|
+$256,453 | 31 Mar 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
3.1%
|
$2,261,479
1,949,551 shares
|
-$2,261,479 | 31 Mar 2025 |
| Neuberger Berman Group LLC |
13F
Company
|
3.1%
|
$740,516
1,968,691 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3%
|
$715,860
1,914,063 shares
|
— | 30 Jun 2026 |
| CM Management, LLC |
13F
Company
|
2.3%
|
$552,211
1,476,500 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$148,898.
Buys
$148,898
Insiders: 2
Sells
$0
Insiders: 0
Net
+$148,898
Shares: +361,469
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 361,469
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 361,469 | 0 | $148,898 | $0 | +$148,898 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Cytosorbents Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Vincent Capponi
Net 12M change
+$148,898
Latest report
15 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vincent Capponi | President and COO | $766,268 | Mixed | 08 Aug 2025 | ||
| Phillip P. Chan | Chief Executive Officer, Director | $750,105 | +$104,898 | +16% | Filing P/S | 12 Jun 2026 |
| Kathleen P. Bloch | Chief Financial Officer | $708,812 | Mixed | 02 Apr 2024 | ||
| Efthymios Deliargyris | Chief Medical Officer | $473,025 | Mixed | 08 Aug 2025 | ||
| Peter J. Mariani | Chief Financial Officer | $280,769 | +$44,000 | +19% | Filing P/S | 15 Jun 2026 |
| Alex D'Amico | Chief Financial Officer | $279,300 | Mixed | 07 Aug 2023 | ||
| Kraus al | Director | $188,921 | Mixed | 06 Feb 2023 | ||
| Michael G. Bator | Director | $151,273 | Mixed | 08 Aug 2025 | ||
| Alan D. Sobel | Director | $147,757 | Mixed | 08 Aug 2025 | ||
| Edward Raymond Jones | Director | $88,834 | Mixed | 08 Aug 2025 | ||
| Jiny Kim | Director | $77,819 | Mixed | 08 Aug 2025 |
Recent insider transactions for Cytosorbents Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Peter J. Mariani | CTSO | Common Stock | Purchase | 18.6% | $44,000 | $0.4400 | 100,000 | 638,113 | 15 Jun 2026 | Direct |
| Phillip P. Chan | CTSO | Common Stock | Purchase | 0.6% | $4,443 | $0.4300 | 10,333 | 1,744,432 | 15 Jun 2026 | Direct |
| Phillip P. Chan | CTSO | Common Stock | Purchase | 16.9% | $100,454 | $0.4000 | 251,136 | 1,734,099 | 12 Jun 2026 | Direct |
| Phillip P. Chan | CTSO | Common Stock | Award | 7.23% | 100,000 | 1,482,963 | 18 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.